| 000 | 01632 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250515170915.0 | ||
| 264 | 0 | _c20090902 | |
| 008 | 200909s 0 0 eng d | ||
| 022 | _a1531-7056 | ||
| 024 | 7 |
_a10.1097/MOG.0b013e32832c073a _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aVan Assche, Gert | |
| 245 | 0 | 0 |
_aImmunosuppression in inflammatory bowel disease: traditional, biological or both? _h[electronic resource] |
| 260 |
_bCurrent opinion in gastroenterology _cJul 2009 |
||
| 300 |
_a323-8 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Review | ||
| 650 | 0 | 4 |
_aAdjuvants, Immunologic _xadministration & dosage |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 |
_aAzathioprine _xadministration & dosage |
| 650 | 0 | 4 |
_aBiological Products _xadministration & dosage |
| 650 | 0 | 4 |
_aColitis, Ulcerative _xdrug therapy |
| 650 | 0 | 4 |
_aCrohn Disease _xdrug therapy |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aInflammatory Bowel Diseases _xdrug therapy |
| 650 | 0 | 4 | _aInfliximab |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aVermeire, Séverine | |
| 700 | 1 | _aRutgeerts, Paul | |
| 773 | 0 |
_tCurrent opinion in gastroenterology _gvol. 25 _gno. 4 _gp. 323-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/MOG.0b013e32832c073a _zAvailable from publisher's website |
| 999 |
_c18846435 _d18846435 |
||